Evaluation of the Safety, Tolerability and Pharmacokinetics of AH-001 Following Topical Single and Multiple Ascending Dose Administration
NCT06927960
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
64
Enrollment
INDUSTRY
Sponsor class
Conditions
Androgenetic Alopecia
Interventions
DRUG:
AH-001 or placebo
Sponsor
AnHorn Medicines Co. Ltd.